AMZN jumps into the pharmacy business, CVS gets “Amazon’d”
With Amazon jumping into the pharmacy business with online prescription fulfillment and free delivery for Prime members, pharmacy stocks like CVS and Walgreens took a hit on Tuesday, both dropping more than 7% pre-market.
Will the selling continue in CVS after pushing to its highest levels, since February, on Monday?
Amazon makes big move into the pharmacy space – #CVS sells off
On Tuesday, news made rounds that Amazon is making its biggest move yet into the pharmacy space, designed to make it easy and convenient to order prescription medicines online.
Amazon Pharmacy has been quietly building out its pharmacy offering for several years:
- It ramped up internal discussions in 2017
- They acquired PillPack in 2018
- PillPack will deliver the infrastructure, including its pharmacy software, fulfillment centers and relationships with health plans.
The service will be available for customers over the age of 18 with the obligation for first time pharmacy customers to answer questions like whether they are pregnant, their date of birth and gender, as it was assigned at birth, which is information required by US law.
With Amazon Pharmacy entering the $300 billion market, the dominance of traditional pharmacies like CVS and Walgreens is in danger. Other large retailers that offer pharmacy services, like Walmart, also pose a similar threat.
As a result, it comes as no big surprise that pharmacy stocks initially sold off sharply, pushing CVS shares down more than 7% in pre-market and Walgreens Boots Alliance dropping more than 8%.
In fact, this isn’t the first time a foray from Amazon into a new market has put pressure on traditional companies in their “home market”: in 2017, for example, Amazon acquired Whole Foods, sending the entire grocery sector into red territory.
That said, CVS shares had trouble gaining back their lost ground on Tuesday and Wednesday, struggling to hold above 70 USD.
It remains to be seen if Amazon Pharmacy can “outplay” CVS in the pharmacy market. Pharmaceuticals are usually not something you order online and medications and side-effects are not usually things people talk about on the phone. Instead, people usually want to speak directly to someone in person.
With the recent sharp push higher in CVS shares from around 55.00 USD to over 70 USD in a matter of two weeks, bulls may have trouble regaining control.
How can you trade #CVS in this environment?
After the dynamic break above the important resistance zone at around 65.00 to 66.00 USD, a re-test of this region might be seen in the near-term. The main question here is certainly whether bulls will quickly regain control.
If so, a near-term stint back above the 70.00 USD mark might be seen, followed by a test of the region around the current yearly highs between 75.00 and 76.50 USD.
Most likely, after an initial bounce higher against 65.00/67.00 USD, another (successful) attempt to break lower will be seen, opening the door for the stock to test the region around 60.00 USD:
Source: Admiral Markets MT5 with MT5SE Add-on #CVS CFD Daily chart (from June 24, 2019, to November 18, 2020). Accessed: November 18, 2020, at 15:00 PM GMT. Please note: Past performance is not a reliable indicator of future results, or future performance.
In 2015, the value of #CVS increased by 1.52%, in 2016, it decreased by 19.29%, in 2017, it decreased by 8.12%, in 2018, it decreased by 9.63%, and in 2019, it increased by 13.39%, meaning that over the past 5 years, the stock is down by 22.13%.
Discover the world’s #1 multi-asset platform
Admiral Markets offers professional traders the ability to trade with MetaTrader 5, allowing you to experience trading at a significantly higher, more rewarding level than with MetaTrader 4. Experience benefits such as the addition of the Market Heat Map, so you can compare various currency pairs to see which ones might be lucrative investments, access real-time trading data, and so much more. Click the banner below to start your FREE download of MT5!
Disclaimer: The given data provides additional information regarding all analysis, estimates, prognosis, forecasts or other similar assessments or information (hereinafter “Analysis”) published on the website of Admiral Markets. Before making any investment decisions please pay close attention to the following:
- This is a marketing communication. The analysis is published for informative purposes only and is in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
- Any investment decision is made by each client alone whereas Admiral Markets shall not be responsible for any loss or damage arising from any such decision, whether or not based on the Analysis.
- Each of the Analysis is prepared by an independent analyst (Jens Klatt, Professional Trader and Analyst, hereinafter “Author”) based on the Author’s personal estimations.
- To ensure that the interests of the clients would be protected and objectivity of the Analysis would not be damaged Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.
- Whilst every reasonable effort is taken to ensure that all sources of the Analysis are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis. The presented figures that refer to any past performance is not a reliable indicator of future results.
- The contents of the Analysis should not be construed as an express or implied promise, guarantee or implication by Admiral Markets that the client shall profit from the strategies therein or that losses in connection therewith may or shall be limited.
- Any kind of previous or modelled performance of financial instruments indicated within the Publication should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
- The projections included in the Analysis may be subject to additional fees, taxes or other charges, depending on the subject of the Publication. The price list applicable to the services provided by Admiral Markets is publicly available from the website of Admiral Markets.
- Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, you should make sure that you understand all the risks.